354 related articles for article (PubMed ID: 17553369)
1. [Rising Prostate Specific Antigen following treatment with curative intention].
Jakobsen H; Pedersen KV
Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy for locally recurrent prostate cancer.
Kirkpatrick JP; Anscher MS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):933-42. PubMed ID: 16555435
[TBL] [Abstract][Full Text] [Related]
3. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
4. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Slawin KM
Nat Clin Pract Urol; 2004 Dec; 1(2):90-6. PubMed ID: 16474521
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
[TBL] [Abstract][Full Text] [Related]
6. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
Simmons MN; Stephenson AJ; Klein EA
Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
[TBL] [Abstract][Full Text] [Related]
7. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
8. PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy.
Gacci M; Serni S; Lapini A; Vittori G; Vignolini G; Nesi G; Carini M
Prostate Cancer Prostatic Dis; 2008; 11(1):99-101. PubMed ID: 17923856
[TBL] [Abstract][Full Text] [Related]
9. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
Tzou K; Tan WW; Buskirk S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
Naito S
Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
[TBL] [Abstract][Full Text] [Related]
12. Rising prostate specific antigen after radical prostatectomy: a case based review.
Nasr R; Goldenberg SL
Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy].
Serra AC; Narbón ES
Arch Esp Urol; 2006 Dec; 59(10):1041-52. PubMed ID: 17283717
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
15. Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies.
Park S; Wians FH; Cadeddu JA
Int J Urol; 2007 Mar; 14(3):251-3. PubMed ID: 17430267
[TBL] [Abstract][Full Text] [Related]
16. [Elevation of PSA after prostate radiotherapy: rebound or biochemical recurrence?].
Toledano A; Chiche R; Lamallem H; Kanoui A; Beley S; Thibault F; Sèbe P
Prog Urol; 2008 Oct; 18(9):557-61. PubMed ID: 18986625
[TBL] [Abstract][Full Text] [Related]
17. Salvage options for biochemical recurrence after primary therapy for prostate cancer.
Bong GW; Keane TE
Can J Urol; 2007 Dec; 14 Suppl 1():2-9. PubMed ID: 18163938
[TBL] [Abstract][Full Text] [Related]
18. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
[TBL] [Abstract][Full Text] [Related]
19. Defining recurrence after radiation for prostate cancer.
Kuban DA; Thames HD; Shipley WU
J Urol; 2005 Jun; 173(6):1871-8. PubMed ID: 15879766
[TBL] [Abstract][Full Text] [Related]
20. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]